


GLOBAL AMR R&D HUB



Global knowledge centre
and driving force for
AMR R&D across the
One Health continuum

About

The Global Antimicrobial Resistance (AMR) Research and Development (R&D) Hub was launched in May 2018, following a call from G20 Leaders, to address challenges and improve coordination and collaboration in global AMR R&D using a One Health approach. The Global AMR R&D Hub supports global priority setting and evidence-based decision-making on allocation of resources for AMR R&D through the identification of gaps, overlaps and potential for cross-sectoral collaboration and leveraging in AMR R&D. It is a global partnership currently consisting of 15 countries, the European Commission and two philanthropic foundations. The work of the Global AMR R&D Hub is steered by a Board of Members.

MEMBERS

- **Australia**
- **Bill & Melinda Gates Foundation**
- **Canada**
- **China**
- **European Commission**
- **France**
- **Germany**
- **Italy**
- **Japan**
- **Netherlands**
- **Norway**
- **Spain**
- **Switzerland**
- **Russia**
- **Turkey**
- **UK**
- **USA**
- **Wellcome**

OBSERVERS

- **OECD**
- **OIE**
- **WHO**

The vision...

...of the Global AMR R&D Hub is to be a key actor having an integrating role in global R&D for AMR, by:

- Bringing together governments and foundations from different world regions, with different research potential and funding priorities, in order to combat the global health threat of AMR
- Setting the focus on addressing global R&D priorities while respecting domestic and organizational priorities
- Promoting high-level coordination and alignment of existing public and private funding and activities and leveraging much needed further monetary and other investments for AMR R&D initiatives on a national and/or international level

Global AMR R&D Hub Secretariat

The Secretariat is located in Berlin. It is staffed with five members and envisions to expand by two more people by the end of 2019.

Focus of the Secretariat

- Developing road map for Dynamic Dashboard
- Launch of Stakeholder Group
- Expert Advisory Group (EAG) to work on determining market potential of interventions addressing the pathogens on the WHO priority pathogens



Activities

The key activity for the Global AMR R&D Hub is to plan, design, build and implement an online Dynamic Dashboard that will present all AMR R&D investments globally across the One Health continuum and is as close to real time as possible.

Activities include:

- Collecting AMR R&D information/data from human, animal, plant and environment health sectors.
- Identifying and inputting AMR R&D data, including incentives, from mapping exercises, initiatives and activities.
- Presenting high level data interactively to allow comparison of R&D activities and funding to identify gaps and duplications.

Additional activities of the Global AMR R&D Hub include:

- Establishing a Stakeholder Group (SG), consisting of approximately 20 members from non-government organisations/civil society, industry, international research funding initiatives and academia, to advise the Hub on specific topics, including the dashboard.
- Establishing an Expert Advisory Group (EAG) to evaluate and determine the market potential of interventions addressing the pathogens on the WHO priority pathogens and tuberculosis.
- Engaging experts and collaborators and seeking consultation through holding workshops, including the upcoming "Increasing Investments for AMR R&D workshop".

Workshop on „Increasing Investments for AMR R&D“

Objective: Identify and discuss opportunities for investments and new and innovative financing mechanisms for AMR R&D.

Expected Outcome: Identification and recommendations of new and innovative mechanisms and opportunities for increasing investment for AMR R&D, including suggestions for implementation and timelines as follows:

- 1 Articulate recommended actions that can be tracked and followed up
- 2 Provide a high-level summary and next steps for the HWG on May 29
- 3 Share outcomes of the meeting

Format: Plenary sessions and panel discussions followed by working group discussions in a breakout session concluding with a report session.

Participants: AMR R&D Hub Members and Observers, further representatives of governments, funders, industry, other investors and other interested stakeholders.

Programme:

WHEN: Tuesday 28 May 2019

WHERE: Geneva, Domaine de Penthes

https://www.gesundheitsforschung-bmbf.de/files/Programme_Workshop_20190528.pdf

Why a Global AMR R&D Hub?

- The increasing emergence and spread of antimicrobial resistance (AMR) is a major global health threat.
- To address the threat of AMR a comprehensive One Health strategy, bringing together human, animal, plant and environmental health sectors, is needed.
- An important component of any strategy is to increase global collaboration of key R&D stakeholders to ensure more efficient use of resources.
- To ensure R&D for AMR remains a priority area for action, there is need to build and maintain political interest and support across the world.

Connection with DZIF

The Secretariat is financed by grants from the German Federal Ministry of Education and Research (BMBF) and the German Federal Ministry of Health (BMG).

The Secretariat administratively belongs to the German Center for Infection Research (DZIF).

Gefördert durch:



Bundesministerium
für Bildung
und Forschung

aufgrund eines Beschlusses
des Deutschen Bundestages

Gefördert durch:



Bundesministerium
für Gesundheit

aufgrund eines Beschlusses
des Deutschen Bundestages

GLOBAL AMR R&D HUB
c/o Unicorn Workspaces
Schlüterstr. 39
10629 Berlin

T +49 30 7262 111 28
globalamrhub@dzif.de
www.globalamrhub.org